You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
NEW YORK – A new genomic, immune profiling, and imaging study suggests there may multiple signatures for predicting response to a PARP inhibitor and checkpoint immunotherapy drug combination in advanced ovarian cancer patients.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?Register for Free.